SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Meadows M. Pregnancy and the drug dilemma. FDA Consum 2001; 35: 1620.
  • 2
    Skomsvoll JF, Wallenius M, Koksvik HS, Rodevand E, Salvesen KA, Spigset O, et al. Drug insight: anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation. Nat Clin Pract Rheumatol 2007; 3: 15664.
  • 3
    Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006; 4: 12558.
  • 4
    Forger F. Infliximab in breast milk [abstract]. Lupus 2004; 13: 753
  • 5
    Ostensen M, Eigenmann GO. Etanercept in breast milk [letter]. J Rheumatol 2004; 31: 10178.
  • 6
    Mahmood I, Green MD. Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharmacol 2007; 47: 154054.
  • 7
    Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99: 238592.
    Direct Link:
  • 8
    Lichtenstein GR, Cohen RD, Feagan BG, Sandbom WJ, Salzberg BA, Chen DM, et al. Safety of infliximab in Crohn's disease: data from the 5000 patient TREAT registry [abstract]. Gastroenterology 2004; 126: A54.
  • 9
    Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005; 21: 7338.
  • 10
    Cush JJ. Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis 2005; 64 Suppl 4: iv1823.
  • 11
    Simpson JL, Jauniaux ER. Pregnancy loss. In: GabbeSG, editor. Obstetrics: normal and problem pregnancies. 5th ed. Philadelphia: Churchill Livingstone; 2007. p. 62949.
  • 12
    Chambers CD, Johnson DL, Jones KL. Pregnancy outcome in women exposed to anti-TNF-α medications: the OTIS Rheumatoid Arthritis in Pregnancy Study [abstract]. Arthritis Rheum 2004; 50 Suppl: S479.
  • 13
    Hyrich KL, Watson KD, Dixon WG, Silman AJ, Symmons DP. Pregnancy experience in women with rheumatic diseases exposed to biologic agents: results from the BSR biologic register [abstract]. Ann Rheum Dis 2006; 65: S321.
  • 14
    Joven BE, Garcia-Gonzales AJ, Ruiz T, Moreno E, Cebrian L, Valero M, et al. Pregnancy in women receiving anti-TNF-therapy: experience in Spain [abstract]. Arthritis Rheum 2005; 52 Suppl: S349.
  • 15
    Joven BE, Garcia-Gonzalez AJ, Ruiz T, Moreno E, Cebrian L, Valero M, et al. Pregnancy in women receiving anti TNF α therapy: experience in Spain [abstract]. Ann Rheum Dis 2006; 65: S317.
  • 16
    Yu XW, Yan CF, Jin HL, Li X. Tumor necrosis factor receptor 1 expression and early spontaneous abortion. Int J Gynecol Obstet 2005; 88: 448.
  • 17
    Winger EE, Reed JL. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol 2008; 60: 816.
  • 18
    Rosner I, Haddad A, Boulman N, Feld J, Avshovich N, Slobodin G, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-α therapy [letter]. Rheumatology (Oxford) 2007; 46: 1508.
  • 19
    Tursi A. Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn's disease [letter]. Dig Liver Dis 2006; 38: 43940.
  • 20
    Angelucci E, Cocco A, Viscido A, Caprilli R. Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception [letter]. Inflamm Bowel Dis 2008; 14: 4356.
  • 21
    Burt MJ, Frizelle FA, Barbezat GQ. Pregnancy and exposure to infliximab (anti tumor necrosis factor α antibody) [letter]. J Gastroenterol Hepatol 2003; 18: 4656.
  • 22
    Kinder AJ, Edwardes J, Samanta A, Nichol F. Pregnancy in a rheumatoid arthritis patient on infliximab and methotrexate [letter]. Rheumatology (Oxford) 2004; 43: 11967.
  • 23
    Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol 2008; 14: 30857.
  • 24
    Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003; 30: 2416.
  • 25
    Koskvik HS, Magnussen AM, Skomsvoll JF. One year follow-up of etanercept exposed pregnancies [abstract]. Ann Rheum Dis 2005; 64: S449.
  • 26
    Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-α therapy. Rheumatology (Oxford) 2007; 46: 6958.
  • 27
    Rump JA, Usadel S, Schonborn H. Pregnancy and etanercept: two cases and follow-up [abstract]. Ann Rheum Dis 2004; 63: S182.
  • 28
    Feyertag J, Dinhof G, Salzer H, Dunky A. Pregnancy in a rheumatoid arthritis patient treated with etanercept [abstract]. Ann Rheum 2004; 63: S198.
  • 29
    Carter JD, Valeriano J, Vasey FB. Tumor necrosis factor-α inhibition and VATER association: a causal relationship. J Rheumatol 2006; 33: 10147.
  • 30
    Sinha A, Patient C. Rheumatoid arthritis in pregnancy: successful outcome with anti-TNF agent (etanercept). J Obstet Gynaecol 2006; 26: 68991.
  • 31
    Micheloud D, Nuno L, Rodriguez-Mahou M, Sanchez-Ramon S, Ortega MC, Aguaron A, et al. Efficacy and safety of etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy. Lupus 2006; 15: 8815.
  • 32
    Otermin I, Elizondo G, Zabaleta J, Amigot A. Etanercept and pregnancy. An Sist Sanit Navar 2007; 30: 4913.
  • 33
    Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy [letter]. Gut 2005; 54: 890.
  • 34
    Kraemer B, Abele H, Hahn M, Rajab T, Kraemer E, Wallweiner D, et al. A successful pregnancy in a patient with Takayasu's arteritis. Hypertens Pregnancy 2008; 27: 24752.
  • 35
    Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Inflamm Bowel Dis 2006; 12: 8278.
  • 36
    Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig Dis Sci 2006; 51: 20457.
  • 37
    Carter JD, Ladhani A, Ricca L, Valeriano J, Vasey FB. A safety assessment of TNF antagonists during pregnancy: a review of the FDA database [abstract]. Arthritis Rheum 2007; 56 Suppl: S41.
  • 38
    Herold M, Schnohr S, Bittrich H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy [letter]. J Clin Oncol 2001; 19: 3439.
  • 39
    Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 2004; 72: 2925.
  • 40
    Friedrichs B, Tiemann M, Salwender H, Verpoort K, Wenger MK, Schmitz M. The effects of rituximab treatment during pregnancy on a neonate [letter]. Haematologica 2006; 91: 14267.
  • 41
    Scully M, Starke R, Lee R, Mackie I, Machin S, Cohen H. Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagul Fibrinolysis 2006; 17: 45963.
  • 42
    Ojeda-Uribe M, Gilliot C, Jung G, Drenou B, Brunot A. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol 2006; 26: 2525.
  • 43
    Magloire LK, Pettker CM, Buhimschi CS, Funai EF. Burkitt's lymphoma of the ovary in pregnancy. Obstet Gynecol 2006; 108: 7435.
  • 44
    Decker M, Rothermundt C, Hollander G, Tichelli A, Rochlitz C. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol 2006; 7: 6934.
  • 45
    Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 2008; 271: 363.
  • 46
    Rey J, Coso D, Roger V, Bouayed N, Belmecheri N, Ivanov V, et al. Rituximab combined with chemotherapy for lymphoma during pregnancy [letter]. Leuk Res 2009; 33: e89.
  • 47
    Ostensen M, Lockshin M, Doria A, Valesini G, Meroni P, Gordon C, et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 2008; 47 Suppl 3: iii2831.
  • 48
    Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005; 353: 1114-23
  • 49
    Botsios C. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev 2005; 4: 16270.
  • 50
    Bristol-Myers Squibb Canada. Orencia (abatacept) product monograph. URL: www.bmscanada.ca/upload/File/pdf/ products/ORENCIA_E_PM_29%20June%2006_APP.pdf.
  • 51
  • 52
    McDuffie RS Jr, Davies JK, Leslie KK, Lee S, Sherman MP, Gibbs RS. A randomized controlled trial of interleukin-1 receptor antagonist in a rabbit model of ascending infection in pregnancy. Infect Dis Obstet Gynecol 2001; 9: 2337.
  • 53
    Simon C, Valbuena D, Krussel J, Bernal A, Murphy CR, Shaw T, et al. Interleukin-1 receptor antagonist prevents embryonic implantation by a direct effect on the endometrial epithelium. Fertil Steril 1998; 70: 896906.
  • 54
    Simon C, Frances A, Piquette GN, el Danasouri I, Zurawski G, Dang W, et al. Embryonic implantation in mice is blocked by interleukin-1 receptor antagonist. Endocrinology 1994; 134: 5218.
  • 55
    Elsmen E, Ley D, Cilio CM, Hansen-Pupp I, Hellstrom-Westas L. Umbilical cord levels of interleukin-1 receptor antagonist and neonatal outcome. Biol Neonate 2006; 89: 2206.